What is the future of treating ALL?
Novel issues in the combined modality treatment of lymphomas
Should we use the word 'cure' in CLL?
Achieving deep responses in previously treated CLL patients
PHILEMON: a step closer to using MRD to guide treatment decisions in mantle cell lymphoma (MCL)?